IrinoSym 40 Injection contains Irinotecan at a concentration of 20 mg/ml and is indicated for the treatment of metastatic colorectal cancer and other malignancies as determined by the prescribing oncologist. Irinotecan is a topoisomerase I inhibitor that interferes with DNA replication by stabilizing the cleavable complex formed between topoisomerase I and DNA, resulting in DNA damage and apoptosis of cancer cells. The injection is administered intravenously under strict medical supervision, typically as part of combination chemotherapy regimens. Dosage and treatment schedules should be individualized based on patient tolerance, tumor response, and hematologic parameters. Common adverse effects include neutropenia, diarrhea, nausea, vomiting, and alopecia, with severe diarrhea requiring prompt management to prevent dehydration. Patients should be monitored closely for signs of infection and gastrointestinal toxicity. IrinoSym 40 Injection is contraindicated in patients with known hypersensitivity to irinotecan or its components and should be used cautiously in individuals with impaired hepatic function. Adequate hydration and supportive care are essential during treatment. This formulation is supplied as a sterile solution for intravenous infusion and must be diluted prior to administration. Proper handling and disposal procedures should be followed to minimize exposure risks to healthcare personnel.